V

    Vanda Pharmaceuticals Inc (VNDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.40
    +0.11 (+2.08%)

    Market Cap: $319.85M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +164.82%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.68
    Range$-0.83 - $-0.58
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.52+22.4%
    60d ago$-0.52+22.4%
    30d ago$-0.51+24.8%
    7d ago$-0.51+24.8%
    Current$-0.68
    Revenue Consensus
    $69M
    Range$61M - $76M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-1.07
    Range$-1.11 - $-0.97
    4 analysts
    Revenue Consensus
    $65M
    Range$56M - $78M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.07---
    Sep 26EST
    		-$-0.68---
    Jun 26
    		$-1.04$-0.51-103.92%Miss-126.1%
    Mar 26
    		$-0.82$-0.69-18.84%Miss-64.0%
    Dec 25
    		$-2.39$-1.32-81.06%Miss-2887.5%
    Sep 25
    		$-0.38$-0.45+15.56%Beat-322.2%
    Jun 25
    		$-0.46$-0.36-27.78%Miss-475.0%
    Mar 25
    		$-0.50$-0.60+16.67%Beat-614.3%
    Dec 24
    		$-0.08$-0.11+27.27%Beat-100.0%
    Sep 24
    		$-0.09$-0.16+43.75%Beat-3850.0%
    Jun 24
    		$-0.08N/A+61.90%Beat-366.7%
    Mar 24
    		$-0.07$0.05-240.00%Miss-216.7%
    Dec 23
    		$-0.04N/A+55.56%Beat-133.3%
    Sep 23
    		$0.00N/A+106.00%Beat-96.0%
    Jun 23
    		$0.03N/A+123.08%Beat-40.0%
    Mar 23
    		$0.06$0.06+0.00%Beat+154.5%
    Dec 22
    		$0.12$0.08+50.00%Beat+0.0%
    Sep 22
    		$0.06$0.09-33.33%Miss-57.1%
    Jun 22
    		$0.05N/A-58.33%Miss-70.6%
    Mar 22
    		$-0.11$-0.01-1000.00%Miss-173.3%
    Dec 21
    		$0.12$0.09+33.33%Beat-20.0%
    Sep 21
    		$0.14$0.18-22.22%Miss+27.3%
    Jun 21
    		$0.17$0.11+54.55%Beat+6.3%
    Mar 21
    		$0.15$0.14+7.14%Beat+66.7%
    Dec 20
    		$0.15$0.14+7.14%Beat+87.5%
    Sep 20
    		$0.11$0.10+10.00%Beat-94.2%
    Jun 20
    		$0.16$0.06+166.67%Beat-42.9%
    Mar 20
    		$0.09$0.01+800.00%Beat+50.0%
    Dec 19
    		$0.08$0.11-27.27%Miss-69.2%
    Sep 19
    		$1.91$0.07+2628.57%Beat+855.0%
    Jun 19
    		$0.28$0.05+460.00%Beat+100.0%
    Mar 19
    		$0.06$0.07-14.29%Miss-57.1%
    Dec 18
    		$0.26$0.13+100.00%Beat+766.7%
    Sep 18
    		$0.20$0.01+1900.00%Beat+766.7%
    Jun 18
    		$0.14$0.02+600.00%Beat+366.7%
    Mar 18
    		$0.14$-0.04+450.00%Beat+227.3%
    Dec 17
    		$0.03$-0.05+160.00%Beat+400.0%
    Sep 17
    		$-0.03$-0.05+40.00%Beat-200.0%
    Jun 17
    		$0.03N/A+115.00%Beat-
    Mar 17
    		$-0.11$-0.13+15.38%Beat-
    Dec 16
    		$-0.01N/A+88.89%Beat-
    Sep 16
    		$-0.01N/A+83.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.17EV/EBITDA0.76x
    Price/FCF-2.27xFCF Yield-43.97%
    Profitability
    Profit Margin-127.40%Operating Margin-126.30%
    ROE-77.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.61xQuick Ratio1.60x
    Trading Statistics
    Beta0.64Avg Volume1.01M
    52-Week High$9.9452-Week Low$4.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.39
    SMA 20$5.26
    SMA 50$5.55
    SMA 200$6.55
    EMA 10$5.35
    EMA 20$5.34
    EMA 50$5.55
    EMA 200$6.04

    MACD

    Line: -0.02Signal: -0.06Hist: 0.04

    ADX

    ADX: 28.8+DI: 15.3-DI: 22.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down32.0
    PSAR$4.93

    Bollinger Bands

    Upper Band$5.61
    Lower Band$4.90
    %B Position1341%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    51.1

    Momentum Oscillators

    Stoch %K70.7
    Stoch %D73.3
    Williams %R-28.4
    ROC (10d)2.7%
    Momentum0.14
    CCI (20d)53.0
    MFI (14d)59.5

    Volatility Measures

    ATR (14d)$0.24(4.4%)
    StdDev (20d)0.18
    Hist Vol43.0%(High)

    Volume Flow

    VWAP$5.35
    OBV49.1M
    AD Line-68.1M
    CMF (20d)0.178

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio0.7x
    VWMA (20d)$5.21

    Pivot Points

    R3$5.63
    R2$5.53
    R1$5.41
    Pivot Point$5.32
    S1$5.20
    S2$5.10
    S3$4.98

    Advanced Oscillators

    TSI-2.39
    Ultimate Osc59.2
    KST-20.92

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$50.53M$51.72M$57.22M$56.26M$52.59M$50.04M$53.19M$47.65M$50.47M$47.46M$45.27M$38.81M
    Cost of Revenue$3.56M$3.16M$3.83M$2.95M$2.74M$3.52M$2.59M$2.55M$2.73M$3.44M$3.46M$3.06M
    Gross Profit$46.97M$48.56M$53.38M$53.30M$49.85M$46.52M$50.59M$45.10M$47.74M$44.02M$41.81M$35.75M
    Operating Expenses$110.78M$98.78M$93.74M$84.59M$88.36M$87.55M$60.87M$56.10M$57.89M$53.26M$48.91M$41.75M
    R&D$36.95M$28.43M$29.01M$22.56M$21.99M$35.71M$19.84M$16.78M$16.66M$21.15M$24.34M$16.60M
    SG&A$71.84M$68.36M$62.98M$60.27M$64.62M$50.08M$39.28M$37.57M$39.47M$30.09M$23.61M$24.77M
    Operating Income$-63,809,000$-50,224,000$-40,353,000$-31,284,000$-38,503,000$-41,028,000$-10,279,000$-11,000,000$-10,146,000$-9,235,000$-7,094,000$-5,995,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-62,384,000$-48,424,000$-38,002,000$-28,390,000$-34,887,000$-37,368,000$-6,497,000$-6,244,000$-5,516,000$-4,664,000$-1,661,000$-120,000
    Income Tax Expense$129,000$143,000$103.19M$-5,804,000$-7,680,000$-7,874,000$-1,585,000$-920,000$-998,000$-518,000$739,000$-257,000
    Net Income$-62,513,000$-48,567,000$-141,187,000$-22,586,000$-27,207,000$-29,494,000$-4,912,000$-5,324,000$-4,518,000$-4,146,000$-2,400,000$137,000
    EBITDA$-58,719,000$-45,033,000$-32,395,000$-26,832,000$-32,551,000$-35,289,000$-4,372,000$-6,254,000$-5,584,000$-3,906,000$-925,000$-2,352,000
    EBIT$-62,384,000$-48,424,000$-38,002,000$-28,390,000$-34,887,000$-37,368,000$-6,497,000$-6,244,000$-5,516,000$-4,664,000$-1,661,000$-120,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VNDA

    Government Contracts

    Gov Obligations (TTM)
    -$5360
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    1.9 mo

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0025Department of Veterans AffairsDepartment of Veterans Affairs$26344Oct 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

    Vanda Pharmaceuticals announced that its NEREUS™ sponsored No. 47 IndyCar, driven by Mick Schumacher for Rahal Letterman Lanigan Racing, will compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. This historic NTT INDYCAR SERIES race on the National Mall celebrates America's 250th anniversary. NEREUS™ (tradipitant) is the first new U.S. prescription medication approved for the prevention of motion-induced vomiting in 47 years.

    Santa Maria Times•8/25/26•
    Somewhat-Bullish

    Vanda receives EU orphan designation for imsidolimab GPP treatment

    Vanda Pharmaceuticals has received European Commission orphan designation for its drug imsidolimab for the treatment of generalized pustular psoriasis (GPP). This designation, the first for a GPP treatment in the EU, offers benefits like regulatory assistance and market exclusivity. Imsidolimab is also under FDA review in the U.S. with a target action date of December 12, 2026.

    grafa.com•8/24/26•
    Bullish

    Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

    Vanda Pharmaceuticals announced that its drug imsidolimab received Orphan Designation from the European Commission for Generalized Pustular Psoriasis (GPP), a severe inflammatory skin disease. This marks the first such recognition for a GPP treatment in the EU, following similar designations in the US and Japan. The drug, which inhibits IL-36 receptor signaling, is also under FDA review with a target action date of December 12, 2026.

    PR Newswire•8/24/26•
    Bullish

    NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

    Vanda Pharmaceuticals Inc. announced that its NEREUS™ sponsored No. 47 IndyCar, driven by Mick Schumacher, will compete in the inaugural Freedom 250 Grand Prix in Washington, D.C. The race, held on the National Mall, celebrates America's 250th anniversary. NEREUS™ (tradipitant) is an FDA-approved medication for motion-induced vomiting, and this sponsorship highlights the brand's focus on performance.

    Fairbanks Daily News-Miner•8/22/26•
    Bullish

    VNDA: Psychiatry Franchise And Pipeline Catalysts Will Drive Future Earnings Repricing

    Vanda Pharmaceuticals' fair value has been reduced from $14.90 to $12.19, reflecting a modest downgrade in its intrinsic value estimate. Analysts trimmed their price target from $17 to $12 due to a Q2 revenue miss, updated revenue growth expectations, and revised profit margins. The company reiterated its full-year 2026 revenue guidance between US$240 million and US$290 million and received Rare Pediatric Disease Designation for its investigational therapy VCA-894A.

    Simply Wall Street•8/20/26•
    Somewhat-Bearish

    Frequently Asked Questions About VNDA

    Does VNDA pay dividends?
    Vanda Pharmaceuticals Inc (VNDA) does not currently pay a regular dividend.
    What is VNDA's market cap?
    Vanda Pharmaceuticals Inc (VNDA) has a market capitalization of $319.85M with a current stock price of $5.40.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In